
FDA expands indication for Eylea to cover all stages of diabetic retinopathy
pharmafile | May 14, 2019 | News story | Manufacturing and Production | Bayer, Eylea, FDA, Regeneron, approval, pharma
The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy.
Regeneron chief scientific officer George Yancopoulos commented: “with today’s FDA approval, Eylea has once again set a high bar for the treatment of diabetic eye diseases.”
The approval was backed by data from the Phase 3 PANORAMA trial of 402 patients. The study found 80% of patients who received the drug every eight weeks experienced an at least 2-step improvement in the Diabetic Retinopathy Severity Scale score versus baseline, compared with 15 percent for placebo.
Eylea was first approved in the US for the treatment of wet age-related macular degeneration in 2011.
The drug is now being studied as a cancer treatment and being co-developed by Bayer and Regeneron for eye diseases.
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …





